Memphasys

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Memphasys has already paid €2.98 in dividends. The last payout was in May 2022.

Financials

In the last quarter, Memphasys had revenue of €158.3K and net profit of -€1.07M

(EUR)	June 2026	YoY
Revenue	158.3K	-
Gross profit	-340.25K	-
Net profit	-1.07M	-
EBITDA	-1.05M	-

Fundamentals

Metric	Value
Market capitalization	€9.69M
Number of shares	3.1B
52-week high/low	€0.00564 - €0.00188
Dividends	No
Beta	0.50
P/E ratio	-3.12
PEG ratio	-0.02
P/B ratio	3.66
P/S ratio	56.53

Company profile

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.